Current and potential oncomarkers in diagnosing breast cancer

• Autorzy: Bilecová-Rabajdová M. , Urban P. , Grešová A. , Varga J. , Gregová K. , Stupák M. , Mareková M.

Warianty tytułu

PL

Obecnie używane i potencjalne markery nowotworowe w diagnostyce raka piersi

• Języki publikacji: EN

Abstrakty

EN

Breast cancer is a very serious disease from both an economical and social point of view, because of its high incidence and mortality, as well as its prevalence. Genetic and epigenetic changes as well as the resultant deregulation of mechanisms that affect cellular processes are reflected in the final stage, like significant variability in phenotype. These changes have multiple factors in clinical, morphological but also molecular terms, and they greatly affect the possibility of accurate diagnosis of breast cancer in its early stages. Since no combination of clinical examination, mammography and ultrasonography together with CT and MRI can achieve 100% sensitivity, clinical practice is supported with diagnostic methods based on the monitoring of tumour markers with the emphasis on molecular markers. This review describes the most common molecular markers already used for earlier clinical diagnostics and also proposes new possible markers from the tumour vascular markers group. Any new oncomarkers to improve diagnostic sensitivity and specificity will be of great benefit, and in clinical practice, they may provide an opportunity for early diagnostic and therapeutic intervention, and subsequently better prognosis for the patient as well.

PL

Rak piersi jest bardzo poważną chorobą, zarówno z punktu widzenia ekonomicznego jak i społecznego, ze względu na dużą zachorowalność i umieralność, a także na zakres jego występowania. Zmiany genetyczne i epigenetyczne, jak również wynikająca z nich deregulacja mechanizmów, które wpływają na procesy komórkowe są odzwierciedlone w ostatnim stadium choroby, jak znaczna zmienność fenotypu. Zmiany te mają wiele przyczyn z punktu widzenia klinicznego, morfologicznego, ale również molekularnego oraz znacznie wpływają na możliwość dokładnego rozpoznania raka piersi w jego wczesnych fazach. Ponieważ żadna kombinacja badań klinicznych, mammografii i USG wraz z tomografią komputerową i obrazowaniem magnetyczno-rezonansowym nie może osiągnąć 100% czułości, praktyka kliniczna jest wspierana metodami diagnostycznymi opartymi na monitoringu markerów nowotworowych, ze szczególnym uwzględnieniem markerów molekularnych. Niniejsza recenzja opisuje najbardziej typowe markery molekularne wykorzystywane we wczesnej diagnostyce klinicznej, a także proponuje nowe potencjalne markery z grupy markerów nowotworowych TVMs . Wszelkie nowe markery nowotworowe poprawiające czułość i dokładność diagnostyki będą bardzo pomocne, a w praktyce klinicznej mogą pozwolić na wczesną diagnostykę i leczenie, co polepszy także rokowania pacjenta.

Słowa kluczowe

EN

breast cancer; diagnostics; molecular markers; tumour vascular markers

PL

rak piersi; diagnostyka; markery molekularne; markery nowotworowe TVMs

• Wydawca: Górnośląska Wyższa Szkoła Pedagogiczna im. Kardynała Augusta Hlonda
• Czasopismo: Journal of Ecology and Health
• Rocznik: 2012
• Tom: R. 16, nr 3
• Strony: 138--143
• Opis fizyczny: Bibliogr. 49 poz.

Twórcy

autor

Bilecová-Rabajdová M.

autor

Urban P.

autor

Grešová A.

autor

Varga J.

autor

Gregová K.

autor

Stupák M.

autor

Mareková M.

• Department of Medical and Chemical Biochemistry and LABMED, Faculty of Medicine

Bibliografia

• [1] Špánik S., Knotek J.: Malignant breast tumours. In: Kaušitz J, Altaner Č, editors. Oncology. Grada publishing, 2003: 412–423.
• [2] Ross J.S., Hatzis C., Symmans W.F.: Commercialized multigene predictors of clinical outcome for breast cancer. The Oncologist 2008; 13: 477–493.
• [3] Banks E., Reeves G., Beral V.: Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Milion Women Study. Cohort study. BMJ 2004; 329: 7464- 477.
• [4] Kajo K., Plank L.: Analysis of gene expression in predicting prognosis and treatment response in cancer exact glands. Oncology 2008; 4: 224-229.
• [5] Hall J.M., Lee M.K., Newman B.: Linkage of early-on-set familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1689.
• [6] Pusztai L., Symmans F.: Histopathologic and molecular markers of prognosis and response to therapy. In: Hunt KK, Rott GL,Strom EA, UETO, NT, editors. Breast Cancer, 2008: 323–339.
• [7] Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes D.R., Bast R.C.: Update of Recommendations for the use of tumour markers in breast cancer. Journal of Clinical Oncology 2007; 25(33): 5287-5312.
• [8] Pusztai L.: Current status of prognostic profiling in breast cancer. The Oncologist 2008; 13: 350–360.
• [9] Lyman G.H., Kuderer N.M.: Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer a metaanalysis. Clin Breast Cancer 2006; 7: 372–379.
• [10] Perou C.M., Sorlie T., Eisen M.G. et al.: Molecular portraits of human breast tumours. Nature 2000; 406: 747–752.
• [11] Payne S.J.L., Bowen R.L., Jones J.L., Wells C.A.: Predictive markers in breast cancer – the present. Histopathology 2008; 52: 82–90.
• [12] Sotiriou C., Wirapati P., Loi S. et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262 –272.
• [13] Duffy M., O Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. A promising tumor biomarker. Cancer Let 2007; 249: 49-60.
• [14] Kenemans P., Verstraeten R.A., Verheijen R.H.: Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas 2008; 61(1-2): 141-150.
• [15] Byoung K., Lee J.W., Park P.J., Sung S., Lee W.Y., Sena Ye., Heesun H., Kang N., Yeo D., Youngdai K., OhnS Y., Noh DY.: The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Research 2009; 22: 1-12.
• [16] Sölétormos G., Nielsen D., Schioler V., Mouridsen H., Dombernowsky P.: Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 2004; 40(4): 481-486.
• [17] Uehara M., Kinoshita T., Hojo T., Akashi-Tanaka S., Iwamoto E., Fukutomi T.: Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. International Journal of Clinical Oncology 2009; 13: 447-445.
• [18] Topolčan O.: Oncogenic markers Indications and interpretations. In vitro diagnostic 2008; 18(10): 13-18.
• [19] Atalay C.: Are CA 15-3, CEA and CA 125 predictors for lymphatic and vascular spread in breast cancer. Erciyes Tip Dergisi 2008; 30: 218-224.
• [20] Agyei-Frempong M.T., Darko E., Addai B.W.: The use of carbohydrate antigen CA 15-3 as a tumor marker in detecting breast cancer. Pakistan Journal of Biological Sciences 2008; 11: 1945-1948.
• [21] Ebeling F.G., Stieber P., Untch M., Nagel D.,  Konecny G.L., Schmitt U.M., Fateh-Moghadam A., Seidel D.: Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. British Journal of Cancer 2002; 86: 1217–1222.
• [22] Masopust J.: Oncology markers yesterday, today and tomorrow. Labor aktuell 2004; 20(2): 4-8.
• [23] Turecký L.: CA125 and the importance of investigation in gynecology. Practical obstetrics 2006; 13(4): 39-45.
• [24] Ye B., Gagnon A., Mok S.C.: Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert review of proteomics 2007; 4: 121-131.
• [25] Sarandakou A., Protonotariou E., Rizos D.: Tumor markers in biological fluids associated with pregnancy. Clinical Laboratory Sciences 2007; 44(2): 151-178.
• [26] Pinto D., Pereira D., Portela C., Leal da Silva J., Lopes C., Medeiros R.: The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochemical and Biophysical Research Communications 2005; 335: 1173–1178.
• [27] Jotwani A.C., Gralow J.R.: Early detection of breast cancer, new biomarker tests on the horizont. Molecular diagnostic a therapy 2009; 13(6): 349-357.
• [28] Bartels C.L., Tsongalis G.: Novel biomarkers for human cancer. Clinical chemistry 2009; 55(4): 623-631.
• [29] Lipton A., Leitzel K., Koestler W., et all.. Prognosis and response predictions-Biomarkers and other factors, Multiple subtypes of HER-2/Neu positive metastatic breast cancer. Cancer Research 2009; 69(24).
• [30] Trinh B., Tjalma W.A., Vermeulen P.B., Van den Eynden G., Van der Auwera I., Van Laere S.J.,  Helleman J., Berns E.M., Dirix L.Y., Van Dam P.: The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. British Journal of Cancer 2009; 100: 971–978.
• [31] Holtz D., Krafty R., Mohamed-Hadley A., Zhang L., Alagkiozidis I., Leiby B., Guo W., Gimotty P., Coukos G.: Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. Journal of Translational Medicine 2008; 6(2): 1-10.
• [32] Mathu S.P., Mathur R.S., Gray E.A., Lane D., Underwood P.G., Kohler M., Creasman W.T.: Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer. Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B. Gynecologic Oncology 2005; 98(3): 467-483.
• [33] Lönneborg A., Dumeaux V., Borresen-Dale A.L.: Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer. Expert Review of Anticancer Therapy 2009; 9(8): 1115-1123.
• [34] Hogdall E.V., Ringsholt M., Hogdall C.K., Christensen I.J., Johansen J.S., Kjaer S.K., Blaaker J., Ontenfeld-Moller L., Price P.A., Christensen L.H.: YKL-40 tissue expresion and plasma levels in patients with ovarian cancer. BMC cancer 2009; 9: 8.
• [35] Roslind A., Knoop A.S., Jensen M.B., Johansen J.S, Nielsen D.L., Price P.A., Balslev E.: YKL-40 expresion in benign and malignant lesions of the breast: a methodologic study. Applied Immunochemistry and molecular morphology 2007; 15(4): 371-381.
• [36] Kucur M., Isman F.K., Balci C., Onal B., Hacibekiroglu M., Ozkan F., Ozkan A.: Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol 2008; 26: 47-52.
• [37] Chong I.W., Chang M.Y., Chang H.C., Yu Y.P., Sheu C.C., Tsai J.R., Hung J.Y., Chou S.H., Tsai M.S., Hwang J.J., Lin S.R.: Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep 2006; 16(5): 981-988.
• [38] Nakamura N., Kobayashi K., Nakamoto M., Kohno T., Sasaki H., Matsuno A., Yokota J.: Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene 2006; 25: 4245–4255.
• [39] Buckanovich R.J., Sasaroli D., O’Brien-Jenkins A., Botbyl J., Hammond R., Katsaros D.: Tumor Vascular Proteins As Biomarkers in Ovarian Cancer. Journal of clinical oncology 2007; 25(7): 852-861.
• [40] Winther-Fjorback A., Kaastrup Müller H., Wiborg O.: Membrane glycoprotein M6B interacts with the human serotonin transporter. J Mol Neuroscience 2009; 37: 191–200.
• [41] Combes P., Bonnet-Dupeyron M.N., Gauthier-Barichard F., Schffman R., Bertini E.: PLP1 and GPM6B intragenic copy number analysis by MAPH in 262 patients with hypomyelinating leukodystrophies: identification of one partial triplication and two partial deletions of PLP1. Neurogenetics 2006; 7(1): 31-37.
• [42] Bilecová-Rabajdová M., Urban P., Grešová A., Birková A., Ostró A., Mareková M.: Tumor Vascular Markers: Possibilities for Detection of Breast Carcinoma. Journal of Chemistry and Chemical Engineering 2012; 6(1), Paper No.: JCHE-E11101101 in press.
• [43] Guicciardi M., Gores G.: Life and death by death receptors. The FASEB Journal 2009; 23(6): 1625-1637.
• [44] Ross J.S, Hatzis C., Symmans WF. et al.: Commercialized multigene predictors of clinical outcome for breast cancer. The Oncologist 2008; 13: 477–493.
• [45] Grewal I.S. et.al.: Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology 2009; 647: 186-195.
• [46] Yang K., Mooney C., Spahlinger G., Schuetze S., et al.: DR6 as a diagnostic and predictive biomarker in adult sarcoma. Plosone 2012;7:5:1-8.
• [47] Bektas N., Haaf A., Veeck J., Wild P.J., Luscher-Firzlaff J., Hartmann A.: Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008; 8: 42.
• [48] Wang I.C., Meliton L., Tretiakova M., Costa R.H., Kalinichenko V.V.: Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 2008; 27: 4137–4149.
• [49] Wang Z., Banerjee S., Kong D., Li Y., Sarkar F.H.: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007; 67: 8293–8300.